Literature DB >> 26836906

Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction.

Philip L Mar1, Victor Nwazue2, Bonnie K Black2, Italo Biaggioni3, André Diedrich4, Sachin Y Paranjape2, James E Loyd2, Anna R Hemnes2, Ivan M Robbins2, David Robertson5, Satish R Raj6, Eric D Austin7.   

Abstract

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) are routinely instructed to avoid performing the Valsalva maneuver for fear of syncope or sudden cardiac death. The mechanism of this action has not been elucidated. We conducted a case-control trial of nine patients with PAH and 15 healthy control subjects to determine if systemic hemodynamic changes during the Valsalva maneuver in these patients invoke greater susceptibility to syncope than healthy control subjects. Metrics commonly employed in autonomic testing were used to assess the degree of autonomic failure.
METHODS: Common Valsalva parameters, including adrenergic baroreflex sensitivity, pressure recovery time, systolic BP (SBP) recovery, diastolic BP (DBP) recovery, mean arterial pressure recovery, and the Valsalva ratio, were calculated. Mann-Whitney U tests were used to compare continuous variables. The primary end point was adrenergic baroreflex sensitivity.
RESULTS: Patients with PAH had lower adrenergic baroreflex sensitivity (9.7 ± 4.6 mm Hg/s vs 18.8 ± 9.2 mm Hg/s; P = .005), longer pressure recovery time (3.6 ± 2.5 s vs 1.7 ± 0.8 s; P = .008), similar SBP recovery (-13 ± 11 mm Hg vs -12 ± 23 mm Hg; P = .640), less DBP recovery (-1 ± 12 mm Hg vs 13 ± 14 mmHg; P = .025), less mean arterial pressure recovery (-5 ± 11 mm Hg vs 5 ± 17 mm Hg; P = .048), and a decreased Valsalva ratio (1.25 ± 0.11 vs 1.60 ± 0.22; P < .001) compared with healthy control subjects.
CONCLUSIONS: Compared with healthy control subjects, patients with PAH are more susceptible to syncope during the Valsalva maneuver because of autonomic dysfunction causing cerebral hypoperfusion. These study patients with PAH exhibited a degree of susceptibility to syncope similar to a spectrum of patients with intermediate autonomic failure who typically experience a SBP drop of 10 to 30 mm Hg with standing.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  autonomic function; autonomic nervous; pulmonary arterial hypertension; syncope

Mesh:

Year:  2016        PMID: 26836906      PMCID: PMC4944774          DOI: 10.1016/j.chest.2015.11.015

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

Review 1.  Testing the autonomic nervous system.

Authors:  Phillip A Low
Journal:  Semin Neurol       Date:  2003-12       Impact factor: 3.420

2.  Blood pressure recovery from Valsalva maneuver in patients with autonomic failure.

Authors:  Elizabeth R Vogel; Paola Sandroni; Phillip A Low
Journal:  Neurology       Date:  2005-11-22       Impact factor: 9.910

3.  Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension.

Authors:  Agnieszka Ciarka; Vi Doan; Sonia Velez-Roa; Robert Naeije; Philippe van de Borne
Journal:  Am J Respir Crit Care Med       Date:  2010-03-01       Impact factor: 21.405

4.  Cardiac sympathetic activation in patients with pulmonary arterial hypertension.

Authors:  Susanna Mak; Klaus K Witte; Abdul Al-Hesayen; John J Granton; John D Parker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-14       Impact factor: 3.619

Review 5.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.

Authors:  D J Williamson; L L Wallman; R Jones; A M Keogh; F Scroope; R Penny; C Weber; P S Macdonald
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

7.  ResearchMatch: a national registry to recruit volunteers for clinical research.

Authors:  Paul A Harris; Kirstin W Scott; Laurie Lebo; Niknik Hassan; Chad Lightner; Jill Pulley
Journal:  Acad Med       Date:  2012-01       Impact factor: 6.893

Review 8.  Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.

Authors:  M Packer
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

9.  Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension.

Authors:  A F Folino; F Bobbo; C Schiraldi; F Tona; S Romano; G Buja; F Bellotto
Journal:  Lung       Date:  2003 Nov-Dec       Impact factor: 2.584

10.  Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension.

Authors:  C L McGowan; J S Swiston; C F Notarius; S Mak; B L Morris; P E Picton; J T Granton; J S Floras
Journal:  Heart       Date:  2009-01-16       Impact factor: 5.994

View more
  6 in total

1.  Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.

Authors:  Jenny Z Yang; Mazen F Odish; Hannah Mathers; Nicole Pebley; Gabriel Wardi; Demosthenes G Papamatheakis; David S Poch; Nick H Kim; Timothy M Fernandes; Rebecca E Sell
Journal:  Pulm Circ       Date:  2022-04-01       Impact factor: 2.886

2.  Estrogen-dependent depressor response of melatonin via baroreflex afferent function and intensification of PKC-mediated Nav1.9 activation.

Authors:  Di Wu; Dan Zhao; Di Huang; Xun Sun; Ke-Xin Li; Yan Feng; Qiu-Xin Yan; Xin-Yu Li; Chang-Peng Cui; Hu-Die Li; Bai-Yan Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

Review 3.  Exercise training in pulmonary arterial hypertension.

Authors:  Laura Adelaide Dalla Vecchia; Maurizio Bussotti
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Effects of a new respiratory muscle training device in community-dwelling elderly men: an open-label, randomized, non-inferiority trial.

Authors:  Sang Hun Kim; Myung-Jun Shin; Jang Mi Lee; Sungchul Huh; Yong Beom Shin
Journal:  BMC Geriatr       Date:  2022-02-24       Impact factor: 3.921

5.  Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.

Authors:  Raj Parikh; Ippokratis Konstantinidis; David M O'Sullivan; Harrison W Farber
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

6.  Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension.

Authors:  Simon Malenfant; Patrice Brassard; Myriam Paquette; Olivier Le Blanc; Audrey Chouinard; Valérie Nadeau; Philip D Allan; Yu-Chieh Tzeng; Sébastien Simard; Sébastien Bonnet; Steeve Provencher
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.